Pingchan granule for depressive symptoms in parkinson’s disease: A randomized, double-blind, placebo-controlled trial

安慰剂 评定量表 医学 内科学 汉密尔顿焦虑量表 帕金森病 汉密尔顿抑郁量表 随机对照试验 物理疗法 萧条(经济学) 焦虑 精神科 重性抑郁障碍 疾病 心理学 发展心理学 替代医学 病理 扁桃形结构 经济 宏观经济学
作者
Si‐Chun Gu,Jie Zhou,Qing Ye,Can‐Xing Yuan
出处
期刊:Journal of Chinese Integrative Medicine [Elsevier BV]
卷期号:19 (2): 120-128 被引量:13
标识
DOI:10.1016/j.joim.2020.12.006
摘要

Depression in Parkinson’s disease (dPD) is closely related to quality of life. Current studies have suggested that Pingchan Granule (PCG) might be effective for treating dPD. This study determines the efficacy of PCG for depressive symptoms in Parkinson’s disease (PD). This was a randomized, double-blind, placebo-controlled trial, conducted in Longhua Hospital, Shanghai, China. Patients diagnosed with idiopathic PD and clinically significant depressive symptoms (defined by a 24-item Hamilton Rating Scale for Depression [HAM-D] score ≥ 8) were included in this study, randomly assigned to PCG or placebo group in a 1:1 ratio and followed for 24 weeks. The primary outcome was the change from baseline to week 24 in HAM-D score among the set of patients who completed the study following the treatment protocol (per-protocol set). Secondary outcomes included changes in scores on the Unified Parkinson’s Disease Rating Scale (UPDRS) part 2 (UPDRS-II), UPDRS part 3 (UPDRS-III), Parkinson’s Disease Sleep Scale (PDSS) and Hamilton Rating Scale for Anxiety (HAM-A), between baseline and week 24. Eighty-six patients were enrolled, and 85 patients were included in the per-protocol set. HAM-D scores decreased by an adjusted mean of 11.77 (standard error [SE] 0.25) in the PCG group and 3.86 (SE 0.25) in the placebo group (between-group difference = 7.91, 95% confidence interval [7.22, 8.80], P < 0.001), in the multivariable linear regression. Improvements in scores on the UPDRS-II, UPDRS-III, PDSS, and HAM-A scales were also observed. Treatment with PCG was well tolerated and improved depressive symptoms and motor and other non-motor symptoms in PD. Chinese Clinical Trial Register: ChiCTR-INR-17011949.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小梅同学完成签到,获得积分10
1秒前
277发布了新的文献求助10
1秒前
2秒前
Jasper的应助被Ian采纳,获得150
2秒前
虚心楼房发布了新的文献求助10
2秒前
马秀玲发布了新的文献求助10
2秒前
2秒前
QIU完成签到 ,获得积分10
2秒前
3秒前
酷波er的应助被良行知采纳,获得10
6秒前
7秒前
酒辞发布了新的文献求助10
7秒前
7秒前
8秒前
喆减一发布了新的文献求助20
8秒前
情怀的应助被dianhuaxue采纳,获得10
9秒前
深情安青的应助被俭朴南风采纳,获得10
9秒前
10秒前
lili完成签到 ,获得积分10
10秒前
爆爆发布了新的文献求助10
10秒前
云海完成签到,获得积分10
11秒前
11秒前
Anna完成签到,获得积分10
12秒前
Licy完成签到,获得积分10
12秒前
12秒前
13秒前
干净的天蓉完成签到,获得积分20
13秒前
科研通AI6.4的应助被王萍有采纳,获得10
13秒前
antrun发布了新的文献求助10
13秒前
14秒前
null的应助被日月雨辰采纳,获得10
14秒前
17秒前
18秒前
Lucas的应助被SFF采纳,获得10
18秒前
动人的电灯胆完成签到,获得积分10
19秒前
CipherSage的应助被Paranoieam采纳,获得10
19秒前
烟花的应助被幸运的成仁采纳,获得10
21秒前
霸气刺猬完成签到,获得积分10
21秒前
21秒前
喆减一完成签到,获得积分20
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183298
求助须知:如何正确求助?哪些是违规求助? 9572606
关于积分的说明 21826444
捐赠科研通 7780272
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558136
邀请新用户注册赠送积分活动 2480259